Associations between tumor response to pembrolizumab and immune-related adverse events in metastatic melanoma patients

被引：0
|
作者：
Geszti, F. [1 ]
Czirbesz, K. [1 ]
Kenessey, I. [1 ]
Liszkay, G. [1 ]
机构：
[1] Natl Inst Oncol, Budapest, Hungary
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
8516
引用
收藏
页码：AB24 / AB24
页数：1
相关论文
共 50 条
  • [21] Incidence of immune-related adverse events with pembrolizumab in advanced melanoma and correlation with treatment response: A single institution review of irAEs.
    Myrdal, Caitlyn N.
    Mehta, Paras
    Smith, Eric
    Briones, Kimberly
    Albright, Jason
    Curiel-Lewandrowski, Clara
    McBride, Ali
    Sundararajan, Srinath
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS SPECTRUM AND PROGNOSIS IN PATIENTS WITH ADVANCED UROTHELIAL CANCER TREATED WITH PEMBROLIZUMAB
    Tamiya, Takashi
    Kijima, Toshiki
    Tanaka, Hajime
    Yoshida, Soichiro
    Ishioka, Junichiro
    Matsuoka, Yoh
    Numao, Noboru
    Sakai, Yasuyuki
    Saito, Kazutaka
    Matsubara, Nobuaki
    Yuasa, Takeshi
    Masuda, Hithoshi
    Yonese, Junji
    Kageyama, Yukio
    Fujii, Yasuhisa
    JOURNAL OF UROLOGY, 2020, 203 : E743 - E744
  • [23] Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab
    Mian, Idrees
    Yang, Ming
    Zhao, Hui
    Shah, Mohsin
    Diab, Adi
    Shannon, Vickie
    Patel, Anisha
    Amaria, Rodabe Navroze
    Giordano, Sharon Hermes
    Suarez-Almazor, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Intracranial Tumor Control After Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma
    Zhang, Michael
    Rodrigues, Adrian J.
    Bhambhvani, Hriday P.
    Fatemi, Parastou
    Pollom, Erqi L.
    Gibbs, Iris C.
    Thomas, Reena P.
    Soltys, Scott G.
    Hancock, Steven L.
    Chang, Steven D.
    Reddy, Sunil A.
    Gephart, Melanie Hayden
    Li, Gordon
    WORLD NEUROSURGERY, 2020, 144 : E316 - E325
  • [25] Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma
    Zhang, Michael
    Rodrigues, Adrian
    Bhambhvani, Hriday
    Fatemi, Parastou
    Pollom, Erqi
    Gibbs, Iris
    Thomas, Reena
    Hancock, Steven
    Soltys, Scott G.
    Chang, Steven D.
    Reddy, Sunil
    Hayden, Melanie
    Li, Gordon
    NEUROSURGERY, 2020, 67 : 292 - 292
  • [26] Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors
    Gault, A.
    Anderson, A. E.
    Plummer, R.
    Stewart, C.
    Pratt, A. G.
    Rajan, N.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 263 - 271
  • [27] Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
    Dawidowska, Anna
    Jagodzinska-Mucha, Paulina
    Kosela-Paterczyk, Hanna
    Jaczewska, Sylwia
    Sobczuk, Pawel
    Chelstowska, Monika
    Kowalska, Maria
    Badziak-Sterczewska, Honorata
    Poleszczuk, Jan
    Rutkowski, Piotr
    Lugowska, Iwona
    CANCERS, 2022, 14 (05)
  • [28] Immune-related Adverse Events in Cancer Patients
    Pallin, Daniel J.
    Baugh, Christopher W.
    Postow, Michael A.
    Caterino, Jeffrey M.
    Erickson, Timothy B.
    Lyman, Gary H.
    ACADEMIC EMERGENCY MEDICINE, 2018, 25 (07) : 819 - 827
  • [29] Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
    Freeman-Keller, Morganna
    Kim, Youngchul
    Cronin, Heather
    Richards, Allison
    Gibney, Geoffrey
    Weber, Jeffrey S.
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 886 - 894
  • [30] Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors
    Angeles, Arkhjamil
    Sonke, Eric
    Thao Phuong Nguyen
    Bahl, Gaurav
    Poon, Vincent Isaac
    Bernstein, Vanessa
    Weppler, Alison Margaret
    Savage, Kerry J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345